46 results
8-K
EX-99.1
MCRB
Seres Therapeutics Inc
9 Jan 24
Regulation FD Disclosure
7:05am
and Limitations of Current Options Top 5 rCDI Treatment Goals % Ranked in Top 3 Prevention of recurrences Prevention of morbidity / mortality Restoring
8-K
EX-99.1
v3wd09gj7cnsbk tszsw
28 Jun 23
Amendments to Articles of Incorporation or Bylaws
8:00am
8-K
EX-99.2
gvx54
9 May 23
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
8:16am
8-K
EX-99.1
mhas qt1x5k0jp6r8bp
27 Apr 23
Entry into a Material Definitive Agreement
7:26am
PRE 14A
fu0oe4 61cz9aka5co
14 Apr 23
Preliminary proxy
4:30pm
S-8
EX-99.1
v2ex mwmwho
30 Dec 22
Registration of securities for employees
4:08pm
8-K
EX-10.1
cptu2tdn2abald3
20 May 21
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
8:30am